Bold Therapeutics Presents Corporate and BOLD-100 Updates at BIO-Europe in Cologne, Germany

Company leadership will deliver key corporate milestones and clinical advancement data for BOLD-100.

VANCOUVER, BC, Nov. 2, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, today announced it will present at BIO-Europe in Cologne, Germany, which is taking place from November 9-11.

Bold Therapeutics addresses high unmet medical needs through innovative mechanisms of action that transform oncology treatment. The company's lead asset, BOLD-100, is a first-in-class ruthenium-based small molecule in a global randomized Phase 2 clinical trial for patients with second-line metastatic colorectal cancer (mCRC). The study evaluates the efficacy, safety, and tolerability of two BOLD-100 dose levels (500 mg/m² and 625 mg/m²) combined with FOLFOX-based standard of care (SOC) versus FOLFOX-based SOC alone.

The company will share key efficacy and tolerability findings from an interim analysis during its BIO-Europe presentation. "Bold Therapeutics has achieved significant corporate and clinical milestones that advance BOLD-100 toward registrational trials," said Jim Pankovich, EVP of Bold Therapeutics. "Results from this interim analysis build on earlier positive Phase 2 findings in gastrointestinal cancers, including biliary tract, gastric, and colorectal cancers. This progress brings BOLD-100 closer to delivering novel treatment options to underserved patient populations."

Presentation Details:

Date: November 9, 2026 (Day 1)

Time: 1:15PM - 1:30PM

Room: Theater A

Forward-looking statements

This news release contains forward-looking statements, including statements about the clinical development of BOLD-100 and anticipated milestones. These statements reflect current expectations and involve risks and uncertainties that could cause actual results to differ materially. The company undertakes no obligation to update these statements, except as required by law.

Contact

Jim Pankovich, EVP
[email protected]
604-262-9899

SOURCE Bold Therapeutics Inc.